Leading Medtechs See Organic Growth Across A Market In Flux
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.
You may also be interested in...
Having a single patient's complete health care information all in one place was a dream that US visionaries began to talk up around a decade ago. The idea was that fast, electronic support for doctors would aid clinical decision making and efficiency. Ten years on, there is still much work to do before the dream is realized, says Philips' Carla Kriwet. But a solution is within reach.
The latest guidance from the UK devices regulator fills in some of the information gaps for companies addressing the Northern Ireland and EU27 markets after this year, seen through the lens of Brexit.
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.